PackGene Biotech

Executive Summary

PackGene Biotech is a US-based contract research and manufacturing organization (CRO/CDMO) specializing in viral vectors and nucleic acids for cell and gene therapy. Founded in 2014 and headquartered in Worcester, Massachusetts, the company offers comprehensive services including AAV and lentivirus packaging, plasmid DNA production, mRNA/LNP solutions, and analytical QC. It supports clients globally from discovery through GMP manufacturing, positioning itself as a key partner in the rapidly growing gene therapy market. The company's stage is pre-clinical, and it is privately held with no disclosed funding or valuation. PackGene's focus on viral vectors and nucleic acids aligns with the increasing demand for manufacturing capacity in the cell and gene therapy sector, driven by pipeline advancements and regulatory approvals. As a CDMO, its success hinges on operational execution, capacity expansions, and client partnerships. The company operates in a competitive landscape but benefits from the tailwind of growing outsourcing trends in biopharma.

Upcoming Catalysts (preview)

• Q4 2026GMP Manufacturing Capacity Expansion70% success
• Q2 2027Strategic Partnership with a Gene Therapy Developer50% success
• Q3 2026Launch of New mRNA/LNP Platform60% success